GlassScriptPhysician profile
Paul Runge
NPI 1881691335
$1,249.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $208 · 2021: $612.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $331.22 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $242.10 | 2019-2021 | |
| Allergan, INC. | $222.16 | 2019-2021 | |
| Genentech USA, INC. | $139.40 | 2019-2021 | |
| Alcon Vision LLC | $110.19 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $44.28 | 2021 | |
| Eyepoint US, INC. | $35.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.29 | 2019 | |
| Alimera Sciences, INC. | $24.48 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.89 | 2021 | |
| Genentech, INC. | $13.75 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Runge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.